The Cervical Intraepithelial Neoplasia (CIN) drugs in development market research report provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cervical Intraepithelial Neoplasia (CIN). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued products.
GlobalData tracks 42 drugs in development for Cervical Intraepithelial Neoplasia (CIN) by 36 companies/universities/institutes. The top development phase for Cervical Intraepithelial Neoplasia (CIN) is phase ii with 15 drugs in that stage. The Cervical Intraepithelial Neoplasia (CIN) pipeline has 34 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Cervical Intraepithelial Neoplasia (CIN) pipeline products market are: PapiVax Biotech, Huazhong University of Science & Technology and MOA Life Plus.
The key targets in the Cervical Intraepithelial Neoplasia (CIN) pipeline products market include Human Papillomavirus Protein E7, Human Papillomavirus Protein E6, and Human papillomavirus type 16 Protein E7.
The key mechanisms of action in the Cervical Intraepithelial Neoplasia (CIN) pipeline product include Human Papillomavirus Protein E7 Inhibitor with four drugs in Phase I. The Cervical Intraepithelial Neoplasia (CIN) pipeline products include 15 routes of administration with the top ROA being Intramuscular and 13 key molecule types in the Cervical Intraepithelial Neoplasia (CIN) pipeline products market including Subunit Vaccine, and DNA Vaccine.
Cervical Intraepithelial Neoplasia (CIN) overview
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is characterized by the abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women ages 25 to 35. Most cases of cervical dysplasia are caused by human papillomavirus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge, and low back pain.
For a complete picture of Cervical Intraepithelial Neoplasia (CIN)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
